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The application of global sensitivity
analysis in the development of a
physiologically based
pharmacokinetic model for m-xylene
and ethanol co-exposure in humans
George D. Loizou*, Kevin McNally, Kate Jones and John Cocker
Computational Toxicology Team, Mathematical Sciences Unit, Health and Safety Laboratory, Buxton, UK
Global sensitivity analysis (SA) was used during the development phase of a binary
chemical physiologically based pharmacokinetic (PBPK) model used for the analysis
of m-xylene and ethanol co-exposure in humans. SA was used to identify those
parameters which had the most significant impact on variability of venous blood
and exhaled m-xylene and urinary excretion of the major metabolite of m-xylene
metabolism, 3-methyl hippuric acid. This analysis informed the selection of parameters
for estimation/calibration by fitting to measured biological monitoring (BM) data in
a Bayesian framework using Markov chain Monte Carlo (MCMC) simulation. Data
generated in controlled human studies were shown to be useful for investigating the
structure and quantitative outputs of PBPK models as well as the biological plausibility
and variability of parameters for which measured values were not available. This
approach ensured that a priori knowledge in the form of prior distributions was ascribed
only to those parameters that were identified as having the greatest impact on variability.
This is an efficient approach which helps reduce computational cost.
Keywords: PBPK modeling, xylene and ethanol coexposure, human volunteer study, global sensitivity analysis,
kinetics
Introduction
Exposures to chemicals in occupational and non-occupational settings have been linked to an
increased incidence of disease (Rappaport, 2012; Rappaport et al., 2014). Understanding the
relationship between exposure and disease typically requires a human health risk assessment (RA;
Sahmel et al., 2010). Ideally, such an assessment must include translation of ambient exposure
concentration to a relevant, biologically eﬀective dose that may, in turn, be related to response
(Bessems and Geraets, 2013; Geraets et al., 2014). Physiologically based pharmacokinetic (PBPK)
models have been used successfully for many years to translate inhalation, dermal and oral exposure
to single environmental chemicals and pharmaceuticals to ‘tissue dosimetry’ or concentrations
within the organs and tissues (Clewell, 1995, 2005; Willhite and Clewell, 1997; Rostami-Hodjegan
and Tucker, 2007; Jamei et al., 2009; Polak et al., 2012).
In reality, people are exposed to mixtures of chemicals present in the environment with
the possibility that components may interact. Interacting chemicals can lead to lower toxicity
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(antagonism) or greater toxicity (synergism, potentiation) than
that expected based on the potency and dose of the individual
chemicals (Krishnan et al., 2002). Pharmacokinetic interactions
can lead to a change in tissue dose of chemicals during
exposure to a mixture compared with single exposures (Krishnan
and Brodeur, 1994). Interestingly, Krishnan et al. (2002)
demonstrated that with the application of PBPK modeling the
extrapolation of binary interactions to more complex mixtures
is possible and that this may aﬀord a basis for a quantitative
chemical mixture RA methodology.
PBPKmodels are independent, structural models, comprising
compartments that correspond directly and realistically to the
organs and tissues of the body connected by the cardiovascular
system (Clewell and Andersen, 1985, 1987, 1994, 1996; Rowland
et al., 2004; NRC, 2007; Zhao et al., 2011). The principle
application of PBPK models is in the prediction of the
appropriate form of the target tissue dose, or dose-metric, of the
parent chemical or its reactive metabolite(s). The dose-metric
must capture the critical biological steps that lead to an eﬀect.
Such mechanisms may take place within any compartment, e.g.,
blood, organ, or sub-cellular compartment. Use of an appropriate
dose-metric in chemical RA calculations provides a better basis
for relating to the observed toxic eﬀects than the external or
administered exposure concentration of the parent chemical
(Conolly and Butterworth, 1995; Barton et al., 1998; IGHRC,
1999; Johanson et al., 1999; Andersen, 2003; Clewell and Clewell,
2008; Lipscomb and Poet, 2008; McNally et al., 2011). Therefore,
PBPK models contain knowledge of the system being studied in
the form of dozens of parameters and inputs that are associated
with uncertainties. Yet, an aspect of the use of PBPK models,
which continues to require study, is whether any particular
model is an adequate representation of the biological system it
is built to emulate. If there are inadequacies and uncertainties
in the PBPK model then the tissue dosimetry estimates will be
wrong. By using data generated from laboratory studies where
both the biological monitoring (BM) outputs and the originating
exposure (input) are known, the PBPK model structure can
be evaluated and any inadequacies addressed. However, in the
environmental and occupational toxicology arena there have
been a limited number of validations of human PBPK models
with BM data obtained in controlled human studies (Tardif et al.,
1993, 1995, 1997; Loizou et al., 1999; Jonsson and Johanson,
2001a, 2002; Jonsson et al., 2001; Krishnan et al., 2002; McNally
et al., 2012). Data generated in controlled human studies are
not only useful for investigating the structure and quantitative
outputs of PBPK models but also the biological plausibility and
variability of parameters for which measured values are not
available (Jonsson and Johanson, 2001a,b, 2002; Jonsson et al.,
2001).
In this report we present the BM results from a controlled
human study where volunteers were exposed to a binary mixture
of ethanol and m-xylene. This combination was selected because
m-xylene metabolism is known to be inhibited by ethanol during
and post-acute ingestion (Riihimäki et al., 1982; Wilson et al.,
1983; MacDonald et al., 2002). We also describe PBPK models
for exposure tom-xylene alone and the binary mixture of ethanol
and m-xylene. A global sensitivity analysis (SA) of both PBPK
models based on the workﬂow proposed by McNally et al.
(2011) is conducted, and the results from the two models are
compared and contrasted. Finally we present the results from
model calibration whereby the sensitive uncertain parameters in
the PBPK model for the exposure to a binary mixture of ethanol
and m-xylene were tuned using a Bayesian approach (McNally
et al., 2012) such that model predictions and observed BM data
were consistent.
Materials and Methods
Volunteers
The UK Health and Safety Executive Research Ethics Committee
approved the study. Volunteers, who all were Health and Safety
Laboratory staﬀ, provided written informed consent before
participating. Eight volunteers, seven male and one female
(aged 29–54; Table 1) took part and were in good health at
the time of the study, did not suﬀer from respiratory disease,
and were not on any medications. Medical assessments were
made immediately before the start and at the end of each
experiment, to ensure that each volunteer was ﬁt to participate
and then to be discharged, respectively. The medical supervisor
was present throughout the exposure period. All volunteers
were asked to refrain from alcohol consumption for at least
72 h before entering the study. Body mass, height, body
mass index (BMI), mass of body fat, resting minute volume,
mean urine ﬂow, urinary creatinine concentration and m-xylene
blood:air partition coeﬃcient (PC) for each volunteer was
measured (Table 1). Body fat was measured using a bio-electrical
impedance analyser (Bodystat 1500 Ltd., Isle of Man, UK) and
by skinfold thickness measurements (Holtain callipers, Holtain
Ltd., Crymych, UK). The value for mass of body fat used was
the mean of the two techniques. Resting minute volume was
measured using a Morgan Medical Pulmolab TF 501 apparatus at
the Respiratory Function Unit of the Royal Hallamshire Hospital,
Sheﬃeld. The alveolar ventilation rate was assumed to be 70% of
minute volume (Brown et al., 1997).
Chemicals
Absolute ethanol, m-xylene (99%) and 3-methylhippuric acid
(98%) were obtained from Aldrich Chemical Co. (Dorset, UK).
All other chemicals used were reagent grade or higher.
Exposure Protocol
Exposures were performed in the Health and Safety Laboratory
Controlled Atmosphere Facility (CAF), a purpose built room
8 m3 in volume. Atmospheres of m-xylene vapor were generated
by purging m-xylene-ﬁlled bubblers with compressed air into
the CAF. The atmospheric concentration within the CAF was
monitored continuously by a Miran infra-red spectrophotometer
(calibrated by an internal, closed-loop system) and by gas
chromatography (Varian 6000, with a 0.05 m % 0.5 mm i.d.,
with 5% OV10, 100–120 mesh Chrom CHP packing; injector
temperature 120◦C; N2 carrier gas ﬂow rate 40 mL min−1; oven
temperature 60◦C) with ﬂame ionization detection (detector
temperature 200◦C, H2 ﬂow rate 25 mL min−1, air ﬂow rate
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TABLE 1 | Measured parameters.
Volunteer Age Body
weight
(kg) (BW)
Height
(m)
BMI
(kg/m2)
Mass of body
fat (% BW)
(VFAC)
Resting alveolar
ventilation rate
(l/h) (QPMC)
Average urine
flow
(l/h) (Rurine )
Average urinary
creatinine (mmol/l)
(CREmmol)
m-xylene
Blood:air partition
coefficient (PBAXYL)
A 54 79 1.68 28.00 0.218 383.3 0.070 14.8 15.1
B 51 61.5 1.78 19.32 0.192 409.3 0.125 7.30 16.8
C 47 89 1.91 24.40 0.169 477.5 0.090 14.9 11.4
D 48 85 1.75 27.80 0.263 362.7 0.091 13.0 18.0
E 29 76 1.85 22.20 0.130 327.2 0.088 12.5 26.5
F 25 76 1.83 22.70 0.162 352.6 0.055 14.8 20.2
G 41 75 1.70 26.00 0.179 462.2 0.076 12.8 –
H 29 68 1.70 23.50 0.299 348.6 0.074 10.2 21.6
Mean 76.2 1.78 24.24 0.202 390.4 0.083 12.5 18.5
SD 8.73 0.08 2.95 0.056 54.89 0.021 2.70 4.90
CV 0.115 0.05 0.122 0.277 0.141 0.247 0.212 0.26
300 mL min−1, calibration using a gas sampling valve against a
standard atmosphere). The CAF temperature was maintained at
25◦C and 30% humidity for all experiments.
Groups of four volunteers were exposed for 4 h on two
separate occasions to a target concentration of 50 ppm m-xylene
vapor. The ﬁrst exposure was to m-xylene only. The second
exposure, which was scheduled 1 month after the ﬁrst, was
started 30 min after the volunteers had ingested 0.8 g kg−1
ethanol, diluted in fruit juice. The actual measured exposure
concentrations for the duration of the experiments were:
45.5 ± 5.7 and 44.1 ± 6.9 ppm, for the exposures without
prior ethanol ingestion, and 45.1 ± 4.7 and 43 ± 10.3 ppm,
with prior ethanol ingestion, respectively. The exposure protocols
and BM are summarized in Table 2. The dose of ethanol
required to inhibit CYP2E1 was obtained from a previous
study, which reported blood m-xylene concentrations in human
volunteers, with and without, prior ingestion of 0.8 g kg−1
ethanol (Riihimäki et al., 1982). The data could be interpreted
as having demonstrated inhibition of m-xylene metabolism
(Riihimäki et al., 1982). However, inhibition of CYP2E1 by
0.8 g kg−1 ethanol was conﬁrmed in this study by measuring
the hydroxylation of the probe substrate, chlorzoxazone (Loizou
and Cocker, 2001). The individual amounts of ethanol and ﬁnal
volume of ﬂuid ingested are listed in Table 3.
Venous blood samples were taken at 0, 0.3, 0.7, 1, 2, 3, 4,
4.33, 4.67, 5, 6, 7, 8, and 23 h. The blood data were separated
into two sets corresponding to measurements made on diﬀerent
days. Unfortunately, ﬁve from eight samples from the exposures
without prior administration of ethanol were deemed unreliable
due to the possible loss of volatilised m-xylene because of
imperfect sealing of sample vials (McNally et al., 2012). Therefore,
it was only possible to compare venous blood concentrations of
m-xylene, with and without prior administration of ethanol, in
just three volunteers.
Exhaled air samples were taken at 0, 4.017, 4.33, 4.67, 5, 6, 7, 8,
and 24 h. Urine samples were taken at 0, 4, 6, 8, 10, 12, 14, 24, 27,
31 h.
Biological Monitoring
Blood (CVxyl) and exhaled alveolar m-xylene (CXppm) and
urinary 3-methylhippuric acid (MHA) concentrations (Curine)
were analyzed. Volunteers provided blood samples from the
TABLE 2 | Exposure protocols and biological monitoring.
Exposure
concentration (ppm)
Biological monitoring
Bloodm-xylene Breath m-xylene Urinary
MHA (g/g creatinine)
Volunteer Ethanol pre-treatment
No Yes No Yes No Yes No Yes
A 45.5 43.0      
B 45.5 43.0 ×     
C 45.5 45.1      
D 45.5 43.0      
E 44.1 45.1 ×     
F 44.1 45.1 ×     
G 44.1 43.0 ×     
H 44.1 45.1 ×     
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TABLE 3 | Individual ethanol doses and calculated gastric emptying rates.
Volunteer Weight (kg) Amount of ethanol (g)
for dose of 0.8 g/kg
Volume of absolute
ethanol (ml)
Final volume diluted 1:4
with fruit juice (ml)
Half-life of gastric
emptying (h)
Gastric emptying
rate Ke(max) (h−1)
A 79 63 80 320 0.122 5.67
B 61.5 49 62 248 0.093 7.49
C 89 71 90 360 0.139 4.99
D 85 68 86 344 0.132 5.24
E 76 61 77 308 0.117 5.91
F 76 61 77 308 0.117 5.91
G 75 60 76 304 0.116 5.99
H 68 54 69 276 0.104 6.67
Mean 76.2 60.9 77.1 308.5 0.117 5.99
SD 8.73 7.04 8.85 35.4 0.015 0.791
CV 0.115 0.116 0.115 0.115 0.128 0.132
antecubital vein via an indwelling soft cannula. Samples were
taken prior to entering the exposure facility and at hourly
intervals during exposure, then every 20 min for the ﬁrst hour
after exiting the exposure facility before returning to hourly
intervals for the next 3 h. A single sample was collected the
next day at 23 h after the start of the study. Blood samples
were stored in sealed vials containing EDTA as anticoagulant
(48 h, maximum) at 4◦C as whole blood until analyzed. Blood
and urine samples were analyzed in duplicate as follows: a
250 μL sample was added to 750 μL of H2O in a 10 mL
headspace vial, which was capped with a PTFE-lined rubber
septum. The sample was then incubated and continually stirred
at 65◦C for 10 min. A 1 mL headspace aliquot was taken
using a pre-warmed (75◦C) gas-tight syringe (Fisons HS800
headspace sampler) and analyzed by gas chromatography (Carlo
Erba GC8000; column BP-5, 25 m 0.32 mm i.d., 5 μm ﬁlm) and
mass spectrometry (Fisons MD800 MS) operating in selected ion
monitoring mode using positive electron ionization (m/z M+
106). The limit of detection of the assay was 0.1 μmol L−1 with
intra- and inter-assay coeﬃcients of variation (CVs) of 5 and 10%,
respectively.
End tidal breath samples (alveolar air) were taken and
analyzed according to the method of (Dyne et al., 1997) and as
described previously (Loizou et al., 1999).
Urine volumewas recorded and samples stored at−20◦C until
analyzed. The major metabolite, 3-methylhippuric acid (3-MHA)
was measured in the urine to assess the rate of biotransformation
and elimination of m-xylene. A 0.5 mL sample of urine was
mixed with 0.5 mL methanol and analyzed by HPLC (Hewlett
Packard 1050 Series, with auto-sampler, pump, degasser; column
3 μm ODS, 100 4.6 mm) with a mobile phase of 0.1% acetic
acid:methanol (85:15 with gradient elution), using diode array
detection at a detection wavelength of 230 nm. The limit of
detection of the assay was 40 μmol L−1, with intra- and inter-
assay CVs of 2 and 5%, respectively.
PBPK Models
Two PBPK models, for m-xylene and ethanol, were
interconnected at the level of the liver as described by Krishnan
et al. (2002), where the chemicals compete for metabolism by
the same enzyme. Only liver metabolism was described since
hepatic microsomal enzyme activities are generally signiﬁcantly
higher than those in other organs (Paciﬁci et al., 1988). Both
models were described previously (Loizou and Spendiﬀ, 2004;
McNally et al., 2012). The ethanol model incorporated a
description of the retardation of gastric emptying due to a
concentration-dependent inhibition of gastric peristalsis by
ethanol (Loizou and Spendiﬀ, 2004). The m-xylene model,
included a bladder compartment to simulate ﬂuctuations in
metabolite concentration in the urine (McNally et al., 2012),
was modiﬁed to describe competitive, non-competitive and
un-competitive inhibition of m-xylene metabolism by ethanol.
Simulations of venous blood concentrations of m-xylene were
run using each of the inhibition mechanisms. Competitive
inhibition was considered to provide the best ﬁt to the data by
simple visual inspection. Initial, deterministic simulations were
conducted using the parameters listed in Tables 3–6.
Partition Coefficients
Pre-exposure blood samples were taken from each volunteer for
the determination of the blood:air m-xylene PCs. The tissue:air
partition coeﬃcients were determined as described previously
(Loizou et al., 1999) according to the method of Gargas et al.
(1989). Tissue:blood PCs were determined by dividing the
tissue:air PCs by the blood:air PC. Surrogate PCs for the slowly
and rapidly perfused compartments were obtained from the
literature (Lapare et al., 1993).
Rat tissue:blood PCs for ethanol determined by Kaneko et al.
(1994) were used as surrogates for human tissue and the human
blood:air PC was obtained from (Pastino et al., 1997) as described
previously (Loizou and Spendiﬀ, 2004).
Parameter Distributions
Anatomical and physiological parameter distributions used for
global SA and Markov-chain Monte Carlo (MCMC) simulations
were obtained from the freely available web-based application
PopGen, which is a virtual (healthy) human population generator
(1McNally et al., 2012). A human population, comprising 50%
male and 50% female, white Caucasians, age range 16–65, height
1http://xnet.hsl.gov.uk/popgen
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TABLE 4 | Anatomical, physiological and kinetic constants and parameters common to both models.
Parameter Abbreviation Value Distribution
Molecular mass m-xylene (g/mol) MWxyl 106.17 –
Molecular mass MHA (g/mol) MWMHA 193.2 –
Body mass (kg) BW Normal BW∼N(76.2,(8.73)2 )
Vascularised tissue (proportion of body mass) VT 0.91 –
Cardiac output (L h−1 BW−0.75) QCMC 13.8 Normal QCMC∼N(13.8,(2.5)2 )
Microsomal protein yield per gram wet weight liver (mg g−1) MPY 34 Lognormal ln(MPY)∼N(37,(2.9)2 )
Gas exchange
Respiratory rate (L h−1 ) QPMC 390.4 Normal QPMC∼N(390.4,(54.9)2 )
Respiratory dead space (proportion respiratory rate) DS 0.3 –
Tissue blood flow as a fraction of cardiac output
Rapidly perfused QRPDC 0.48 –
Slowly perfused QSPDC 0.22 Uniform QspdC ∼U(0.2–0.35)
Adipose QFAC 0.05 Normal QfaC∼N(0.053,(0.003)2 )
Liver QLIC 0.25 Normal QliC∼N(0.271,(0.01)2 )
Tissue mass as a fraction of body mass
Rapidly perfused VRPDC 0.09 –
Slowly perfused VSPDC 0.604 –
Adipose VFAC 0.19 Lognormal ln(VfaC)∼N(-1.59,(-2.88)2 )
Liver VLIC 0.0257 Normal VliC∼N(0.036,(0.01)2 )
Bladder compartment
Rate of urine production (L h−1 ) Rurine 0.07 Normal Rurine∼N(0.083,(0.021)2 )
Urinary creatinine concentration (mmol L−1 ) CREmmol 12.5 Normal CREmmol∼N(12.5,(2.7)2 )
First-order elimination rate constant (h−1 ) K1 20 Uniform K1∼U(5–20)
TABLE 5 | Parameters specific to them-xylene model.
Molecular masses
Molecular mass m-xylene
(g/mol)
MWxyl 106.17 –
Molecular mass MHA (g/mol) MWMHA 193.2 –
Metabolism (liver)
In vitro Michaelis constant
(mMol L−1 )
KM2E1xyl 11.8 Normal
KM ∼N(11.8,(1.4)2 )
In vitro maximum rate of
metabolism (pmol
min−1 mg−1 microsomal
protein)
Vmax2E1xyl 895 Normal
Vmax ∼N(895,(68)2 )
Inhibitory rate constant
(mg L−1 )
KI 10 Uniform
KI∼U(1–20)
Partition coefficients
Blood:air partition coefficient PBAXYL 18.5 Normal
Pba∼N(18.5,(4.9)2 )
Rapidly perfused PRPDAXYL 117 Uniform
Prpda∼U(50–150)
Slowly perfused PSPDAXYL 53 Uniform
Pspda∼U(40–80)
Adipose PFAAXYL 1874 Uniform
Pfaa∼U(1400–2200)
Liver PLIAXYL 279 Uniform
Plia∼U(150–350)
range 140–200 cm, body mass indices 18.5–30 was generated to
encompass the characteristics of the volunteers that took part in
the study. Most anatomical and physiological parameters were
common to both the m-xylene and ethanol models (Table 4).
The following parameters diﬀered; metabolic rate constants,
PCs and those describing the inhibition of gastric motility
(Tables 5 and 6).
Apart from the blood:air PC for m-xylene, no distributions
were available for the PCs, therefore, uniform distributions
were assigned and the ranges set were considered reasonable
assumptions. VspdC and VrpdC, the masses of the slowly and
rapidly perfused tissues respectively, were not included in the SA
because they are aggregated compartments from which organs
and tissues are subtracted when discretely deﬁned to maintain
tissue mass balance. Uniform distributions were assigned to
the ethanol-model-speciﬁc parameters as only point values were
originally reported (Pastino et al., 2000; Loizou and Spendiﬀ,
2004). The model was re-parameterised as proposed by Gelman
et al. (1996) to ensure that mass balance and blood blow
constraints were not violated.
Sensitivity Analysis
A two-phased global SA was conducted following the workﬂow
proposed in McNally et al. (2011). In the ﬁrst phase the Morris
Screening test was used to eliminate the parameters with a
negligible eﬀect on model output. The Morris test results are
not discussed in detail; however, this reduced the number of
varying parameters in the binary model from 47 to 10 or 12.
These less sensitive parameters were subsequently ﬁxed at central
values. In the second phase a reduced number of parameters
were analyzed using the extended Fourier Amplitude Sensitivity
Test (eFAST) to obtain quantitative variance-based measures
of sensitivity. eFAST produces two sensitivity indices for each
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TABLE 6 | Parameters specific to the ethanol model.
Parameter Abbreviation Value Distribution
Molecular mass ethanol (g/mol) MWeth 46.07 –
Gastric compartment
Oral dose (mg) PORALDOSE 800 Uniform PORALDOSE ∼U(480–720)
Drink time (h) DRINKTIME 0.25 Uniform DRINKTIME ∼U(0.2–0.3)
Drink volume (L) DRINKVOL 0.5 Uniform DRINKVOL ∼U(0.4–0.6)
Stomach permeability (h−1 ) BELLYPERM 0.685 Uniform BELLYPERM ∼U(0.548–0.822)
Gut permeability (h−1 ) GIPERM 21.1 Uniform GIPERM ∼U(20.8–30.12)
Maximum emptying rate (h−1) KEmax 10.2 Uniform KEmax ∼U(8.16–12.24)
Minimum emptying rate (h−1 ) KEmin 0.005 Uniform KEmin ∼U(0.004–0.006)
Tissue mass as a fraction of body mass
Stomach VSTC 0.02 Uniform VstC ∼U(0.016–0.024)
Gut VGUC 0.085 Uniform VguC ∼U(0.068–0.102)
Tissue blood flow as a fraction of cardiac output
Stomach QSTC 0.01 Uniform QstC ∼U(0.0056–0.0084)
Gut QGUC 0.17 Uniform QguC ∼U(0.136–0.204)
Metabolism (liver)
In vitro Michaelis constant (mMol L−1 ) KM2E1eth 12.5 Uniform KM2E1∼U(9.98–14.9)
In vitro maximum rate of metabolism (pmol min−1 mg−1 microsomal protein) Vmax2E1eth 12060 Uniform Vmax2E1∼U(9649–14473)
In vitro Michaelis constant (mMol L−1 ) KMαα 4.2 Uniform KMαα∼U(3.36–5.04)
In vitro maximum rate of metabolism (pmol min−1 mg−1 microsomal protein) Vmaxαα 18327 Uniform Vmaxαα ∼U(14661–21993)
In vitro Michaelis constant (mMol L−1 ) KMββ 0.05 Uniform KMββ ∼U(0.04–0.06)
In vitro maximum rate of metabolism (pmol min−1 mg−1 microsomal protein) Vmaxββ 5934 Uniform Vmaxββ ∼U(4747–7121)
In vitro Michaelis constant (mMol L−1 ) KMγγ 0.63 Uniform KMγγ ∼U(0.5–0.54)
In vitro maximum rate of metabolism (pmol min−1 mg−1 microsomal protein) Vmaxγγ 11895 Uniform Vmaxγγ ∼U(9516–14274)
Partition coefficient
Blood:air partition coefficient Pbaeth 1265 Uniform Pbaeth ∼U(1012–1518)
Rapidly perfused Prpdaeth 0.95 Uniform Prpdaeth ∼U(0.76–1.14)
Slowly perfused Pspdaeth 0.80 Uniform Pspdaeth ∼U(0.64–0.96)
Adipose Pfaaeth 0.11 Uniform Pfaaeth ∼U(0.088–0.132)
Liver Pliaeth 0.81 Uniform Pliaeth ∼U(0.648–0.972)
Stomach Psteth 0.81 Uniform Psteth ∼U(0.648–0.972)
Gut PGUeth 0.81 Uniform PGUeth ∼U(0.648–0.972)
parameter: the main eﬀect sensitivity index Si quantiﬁes the
importance of the parameter in isolation whereas the total eﬀect
sensitivity index STi additionally quantiﬁes the interactions with
other model parameters. The diﬀerence between STi and Si is
therefore a measure of interactions alone. The sensitivity indices
were calculated over a speciﬁed portion of the concentration-
time simulation, these were: 0–8 h for CVxyl, 0–10 h for
CXppm, and 0–15 h for Curine. In each case, the speciﬁed
portion of the concentration-time simulation was selected to
investigate the parameter sensitivities during the phases of
greatest change, i.e., uptake, distribution and elimination and
to avoid the regions where sensitivity measures reﬂect sampling
variability and noise rather than important model structure
(McNally et al., 2011). SA results were computed on a ﬁne
timescale. The sensitivities of CVxyl and CXPPM at the 3 and
6-h time points within the distribution and elimination phases
respectively, and at 6 and 10 h for Curine in the early and latter
urinary elimination phases are reported as broadly representative
of the SA results: from 0 to 4 h ‘absorption into the body’
and the period after 4 h ‘elimination from the body’ for
CVxyl and CXPPM, and 4–8 h ‘rapid elimination’ and after 8 h
‘return to baseline’ for Curine. Lowry plots (McNally et al., 2011,
2012) are used to visualize results from the SA at these time
points.
Calibration
Calibration describes the process of tuning the PBPK model
parameters such that the time-varying predictions of model
output CVxyl, CXPPM, and Curine are consistent with observed (in
this case BM) data. The most sensitive parameters were identiﬁed
by SA therefore the computational burden of calibration was
reduced by focussing on just these sensitive parameters. The
measured parameters, body mass (BW), fat mass (VfaC),
resting alveolar ventilation rate (QPMC), urine ﬂow (Rurine),
and urinary creatinine (CREmmol) were known for each
individual (Table 1) and therefore ﬁxed. Although the m-xylene
blood:air PC (Pbaxyl) was measured this parameter was also
calibrated. This is because blood:air PCs are known to vary with
consumption of food (Jonsson et al., 2001) and could therefore
change signiﬁcantly fromwithin day and day to day. The “in vivo”
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KM value, 12.5 mM (575 mg L−1) for the hepatic microsomal
oxidation of ethanol was used as an initial value for the inhibitory
rate constant KI, for the inhibition of hepatic cyp450 m-xylene
metabolism (Derr, 1993). However, this value was ineﬀective,
therefore, KI was also calibrated.
The most sensitive unknown parameters as identiﬁed and
quantiﬁed in SA were calibrated using a Bayesian approach
described previously (McNally et al., 2012). Brieﬂy, the
diﬀerences between model predictions and BM data were
assumed to follow a lognormal distribution. A MCMC algorithm
was used to sample values for the most sensitive unknown
parameters. The posterior modal parameter set that is, the
parameter set which results in the lowest discrepancy between
predictions and BM data was extracted from the MCMC output
and compared with the BM data so the overall adequacy of the
model could be assessed.
Software
The numerical solutions to the model equations were obtained
using acslX Libero version 3.0.1.6 (AEgis Technologies2). The
M functions for eFAST and MCMC modeling included with
the acslX Optimum suite of tools were adapted for use in this
study. Lowry plots were created using a bespoke web application
developed by the authors3. All other ﬁgures were created using
GraphPad Prism 4 for Windows4. A Dell Optiplex 755 Intel
Core(TM)2 Duo CPU 3.00GHz 2.00GB RAM was used for all
simulations in this study.
Results
Sensitivity Analysis
The information obtained from global SA is presented using two
ﬁgures for each of the studied model outputs. Figures 1, 3, and 5
show the change in proportion of variance of the main eﬀects
Si, over time for the parameters selected for eFAST for CVxyl,
CXppm, and Curine, respectively. In each ﬁgure Panel A shows
the main eﬀects of parameters with no inhibition, and Panel B
with inhibition by ethanol. The most dominant parameters are
represented by broken lines. The inhibitory rate constant KI,
was also represented as a broken line irrespective of contribution
to variance. Figures 2, 4, and 6 show plots of main eﬀects and
interactions terms at 3 and 6 h for CVxyl, CXppm and at 6 and
10 h for Curine, respectively: the chosen time points are snapshots
of the sensitivities in the distribution and elimination phases,
respectively. In each ﬁgure Panel A shows the main eﬀects of
parameters with no inhibition, and Panel B with inhibition by
ethanol.
Venous Blood m-Xylene
In the absence of inhibition of m-xylene metabolism, PBAXYL
was initially dominant in simulations of CVxyl (Figure 1A) with
a gradual decrease to the end of the exposure period at 4 h. The
2http://www.acslx.com/
3http://lowryplot.appspot.com/
4www.graphpad.com
main eﬀect for QPMC was also large and near constant after the
ﬁrst hour of exposure. The main eﬀect for MPY steadily increased
in importance throughout the simulated 4 h. The main eﬀects of
the three most inﬂuential parameters from 0.5 to 4 h accounted
for 68.9 to 72.3%5 of variance with PBAXYL, the most dominant,
ranging from 40.8 to 44.8% (Figure 1A). The Lowry plot shown
in Figure 2A indicates that interactions were generally small. The
main eﬀects of the three most inﬂuential parameters from 5 to
8 h accounted for 48.3–66.4% of variance with MPY, the most
dominant, ranging from 20.7 to 31.6% (Figure 1A). In summary,
PBAXYL and MPY were the most dominant parameters from
1.0 to 8 h together accounting for 27.9–53.9% of variance. No
other individual parameter accounted for greater than 19.2% of
variance at any time.
In the presence of inhibition of m-xylene metabolism the
main eﬀects of the three most inﬂuential parameters from 0.5
to 4 h accounted for 65.7–83.9% of variance (Figure 1B). The
main eﬀect of PBAXYL was the dominant parameter between 0.5
and 4 h, accounting for between 42.9 and 65.6% of variance. The
main eﬀect of PBAXYL declined sharply in the last hour of the
exposure. CVxyl had reduced sensitivity to both QPMC and MPY
compared to the simulations without inhibition (Figures 1A,B)
for the duration of the exposure (0–4 h). Figure 1B shows that
the main eﬀect of MPY was close to zero in the ﬁrst 2 h and
began to sharply increase in importance after 3 h of exposure.
The interactions between inputs were still modest between 0.5
and 4 h however, Figure 2B indicates some small interactions
between the parameters governing the rate of metabolism of
m-xylene in this time period (particularly MPY and KI). Whilst
the detailed analysis at 3 h is intended to be broadly representative
of overall parameter sensitivity in the ﬁrst 4 h, it is clear from
Figure 1B that results after 3 h are time sensitive, due to rapid
changes in the sensitivity to PBAXYL and MPY and interaction
terms. The main eﬀects of the three most inﬂuential parameters
from 5 to 8 h accounted for 67.2–80.4% of variance with MPY,
the most dominant, ranging from 42.2 to 69.7% (Figure 1B).
The interaction terms were more signiﬁcant in this period as
indicated by the width of the plume (Figure 2D). Two clusters
of interacting parameters were observed: the ﬁrst concerned
interactions between PBAXYL, BW and VSPDC and VFAC (as
seen in both Figures 2C,D); the second concerning interactions
between parameters governing metabolism (MPY, PORALDOSE,
and KI).
The switch from PBAXYL to MPY from exposure to post-
exposure periods is consistent with a decrease in the hepatic
concentration of ethanol which, combined with the relatively
high KM and therefore, lower aﬃnity for ethanol metabolism by
the cytochrome P450 (CYP450) enzyme compared to m-xylene,
is consistent with decreased competition with m-xylene for
metabolism.MPY can be seen as an indication of the contribution
of metabolism to variance because MPY signiﬁcantly aﬀects the
magnitude of Vmax in the in vitro–in vivo scaling calculation.
5The ranges of cumulative contribution to variance by the three most inﬂuential
parameters within a speciﬁed time period were obtained by using a spreadsheet to
sort the parameter main eﬀects from largest to smallest for each time point shown
in Figures 1, 3, and 5, and then calculating the sum total.
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FIGURE 1 | Parameter main effects. Change in proportion of variance over time for venous blood concentration of m-xylene (CVxyl): (A) without inhibition of
m-xylene metabolism and (B) with inhibition of m-xylene metabolism. The broken lines represent the most dominant parameters over the entire simulation.
Parameter abbreviations are listed in Table 4.
Exhaled m-Xylene
In the absence of inhibition of m-xylene metabolism PBAXYL
was the dominant parameter throughout the simulation period
with the main eﬀect accounting for between 53.7 and 75.2% of
variance (Figure 3A). QPMC was also an important parameter
throughout the simulation period whereas MPY increased
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FIGURE 2 | Lowry plot of the eFAST quantitative measure for variance in venous bloodm-xylene concentration (CVxyl). (A,C) Shows the total effects
without inhibition of m-xylene metabolism and (B,D), with inhibition at 3 and 6 h after initiation of the simulation. Parameter abbreviations are listed in Table 4.
in importance after the exposure terminated (at 4 h). The
SA identiﬁed the same subset of important parameters for
CXppm as for CVxyl although the contributions to variance
diﬀered. The detailed analysis at 3 h (Figure 4A) showed
interactions were negligible. The detailed analysis at 6 h showed
the SA of CXppm broadly followed the results from CVxyl
with the same inﬂuential parameters observed and interactions
between PBAXYL, BW and the VSPDC and VFAC tissues
(Figure 4C).
In the presence of inhibition of m-xylene metabolism the
SA showed that whilst PBAXYL remained the most important
parameter in the exposure period the main eﬀect accounted for
a smaller proportion of variance ranging from 32.3 to 72.0%
(Figure 3B). The main eﬀects of the three most inﬂuential
parameters from 1.0 to 4 h accounted for 60.7–84.4% of variance.
Figure 3B shows that the main eﬀect of MPY was close to zero
in the ﬁrst 2 h and began to sharply increase in importance
after 3 h of exposure. The detailed analysis in Figure 4B showed
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FIGURE 3 | Parameter main effects. Change in proportion of variance over time for end-exhaled concentration of m-xylene (CXppm): (A) without inhibition of
m-xylene metabolism and (B) with inhibition of m-xylene metabolism. The broken lines represent the most dominant parameters over the entire simulation.
Parameter abbreviations are listed in Table 4.
some small interactions, principally between parameters related
to metabolism (MPY, PORALDOSE, and KI).
The main eﬀects of the three most inﬂuential parameters
from 5 to 8 h accounted for 65.5–81.7% of variance with MPY,
the most dominant, ranging from 52.3 to 65.1% (Figure 3B).
The interactions between parameters governing metabolism were
larger in this period (Figure 4D).
In summary, PBAXYL and MPY were the most dominant
parameters from 1.0 to 8 h together accounting for
45.3–76.2% of variance. No other individual parameter
accounted for greater than 18.9% of variance at any
time.
Urinary 3-Methylhippuric Acid
In the absence of inhibition of m-xylene metabolism, Rurine
and CREmmol were the most dominant parameters governing
variance in urinary excretion of 3-MHA up to 8 h post-
exposure when PBAXYL began to exceed CREmmol, albeit
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FIGURE 4 | Lowry plot of the eFAST quantitative measure for variance in venous bloodm-xylene concentration (CXppm). (A,C) Shows the total effects
without inhibition of m-xylene metabolism and (B,D), with inhibition at 3 and 6 h after initiation of the simulation. Parameter abbreviations are listed in Table 4.
slightly (Figure 5A) and BWandVFAC increased in importance6.
6The time trends in the main eﬀect plots appear unusual compared with equivalent
plots for exhaled breath and blood and two features are worthy of further
explanation. The ‘blocky’ structure on the main eﬀect plots results from the
sensitivity analysis results only changing after a micturition event which were
simulated every 2 h. Secondly, the increase in importance of PBAXYL at 10 h,
and to a lesser extent body mass (BW) and VFAC are not intuitive. There was a
very rapid decrease in total variance between 4 and 6 h and a further very large
reduction between 6 and 8 h. Plots of the main eﬀect variances (as opposed to the
sensitivity indices plotted here) show the main eﬀect variances of each parameter
decrease over the period of the simulations, however, the two parameters related
to the dilution of 3-MHA in urine decreased at a slower rate compared with other
parameters and thus accounted for a greater proportion of the variance in the 6–8
period.
The main eﬀects of the two most inﬂuential parameters from 4 to
12 h, Rurine and CREmmol accounted for 57.1–85.4% of variance
(Figure 5A). No other individual parameter accounted for greater
than 17.6% of variance at any time. Figures 6A,C are typical
Lowry plots for Curine at 6 and 10 h showing the most inﬂuential
parameters in the absence of ethanol and therefore, no inhibition
ofm-xylene metabolism.
However, in the presence of inhibition of m-xylene
metabolism by ethanol MPY became the most dominant
parameter governing variance in urinary excretion of 3-
MHA (Figure 5B). The main eﬀect of the most inﬂuential
parameter, MPY, from 4 to 14 h accounted for 44.6–66.7%
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FIGURE 5 | Parameter main effects. Change in proportion of variance over time for urinary excretion of 3-methylhippuric acid (Curine): (A) without inhibition of
m-xylene metabolism and (B) with inhibition of m-xylene metabolism. The broken lines represent the most dominant parameters over the entire simulation.
Parameter abbreviations are listed in Table 4.
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FIGURE 6 | Lowry plot of the eFAST quantitative measure for variance in venous bloodm-xylene concentration (Curine). (A,C) Shows the total effects
without inhibition of m-xylene metabolism and (B,D), with inhibition at 6 and 10 h after initiation of the simulation. Parameter abbreviations are listed in Table 4.
of variance (Figure 5B). Rurine increased in proportion of
variance from 6.9 to 22.4% from 4 to 10 h post-exposure.
No other individual parameter accounted for greater than
11.1% of variance at any time. The switch in the importance
of MPY, from insigniﬁcance in the absence of ethanol, to
the most dominant parameter in the presence of ethanol
is consistent with metabolism being an important process
for the removal of m-xylene. Figures 6B,D show the most
inﬂuential parameters governing variance of Curine at 6
and 10 h in the presence of inhibitory concentrations of
ethanol.
The width of the plume indicates that the amount of variance
due to interactions ranged from 6.2 and 0.8% (Figures 6A,C)
in the absence of inhibition to 17 and 22% with inhibition
(Figures 6B,D). It is noteworthy that in the presence of
inhibition, the proportion of variance due to interactions from
MPY, KI and PORALDOSE suggest that these parameters
are perhaps interacting with each other. This is particularly
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pronounced at 10 h post-exposure (Figure 6D). This may be
expected as the model equations use these parameters to describe
metabolism. These results also suggest an interaction between
VFAC and BW which together determine the mass of adipose
tissue.
Simulation of Venous Blood m-Xylene
Figure 7A shows the simulated time proﬁles for CVxyl, with
and without prior administration of ethanol, for a single subject.
This data is representative of the three subjects for whom good
measured venous blood data were available. Both predictions
were made using the measured parameters for volunteer A
(Table 1) and a mean value for MPY = 34 mg g−1 (Barter et al.,
2007). Also, since the value of the inhibitory rate constant, KI
obtained from the literature was ineﬀective (Derr, 1993), a value
of 6.57mg L−1 was estimated via the calibration exercise and used
for all simulations.
Figure 7B shows the same data where the prediction,
without prior ethanol administration, was obtained using
measured parameters for volunteer A and calibrated values
for the most sensitive parameters, MPY = 38.84 mg g−1
and PBAXYL = 22.73. Likewise, the prediction, with prior
ethanol administration, was obtained using measured parameters
for volunteer A and calibrated values for the most sensitive
parameters, MPY = 70.35 mg g−1 and PBAXYL = 22.04 and
KI = 6.57 mg L−1.
Simulation of Exhaled Airm-Xylene
Figure 8A shows the simulated time proﬁles for CXppm, with and
without prior administration of ethanol, for a single subject. This
data is representative of all eight subjects. Both predictions were
made using the measured parameters for volunteer E (Table 1)
and a mean value for MPY= 34 mg g−1.
Figure 8B shows the same data where the prediction, without
prior ethanol administration, was obtained using measured
parameters for volunteer E and a calibrated value for the
most sensitive parameter, MPY = 60.96 mg g−1. Likewise, the
prediction, with prior ethanol administration, was obtained using
measured parameters for volunteer E and the calibrated value for
the most sensitive parameter, MPY= 65.66 mg g−1.
Simulation of Urinary 3-Methylhippuric Acid
Figure 9A shows the simulated time proﬁles for Curine, with and
without prior administration of ethanol, for a single subject. This
data is representative of all eight subjects. The step-like shape
of the simulations is the result of the imitation of micturition
where the bladder is assumed to ﬁll with urine at a constant
(but adjustable) rate and empty at discrete time intervals (when
the volume of urine reduces to zero). This enables comparison
between model predictions and experimental observations with
timed sampling in human volunteer studies (Franks et al., 2006;
McNally et al., 2012). Both predictions were made using the
measured parameters for volunteer H (Table 1) and the mean
value for MPY = 34 mg g−1 and KI = 6.57 mg L−1.
Figure 9B shows the same data where the prediction, without
prior ethanol administration, was obtained using measured
parameters for volunteer H and a calibrated value for the
most sensitive parameter, MPY = 43.84 mg g−1. Likewise, the
prediction with prior ethanol administration, was obtained using
measured parameters for volunteer H and the calibrated value
for the most sensitive parameters, MPY = 54.12 mg g−1 and
KI = 6.57 mg L−1.
Discussion
In this study, global SA was used during the model development
phase to identify those parameters which had the most
signiﬁcant impact on variability of CVxyl, CXppm, and Curine.
This information informed the selection of parameters for
estimation/calibration by ﬁtting to measured BM data in a
Bayesian framework using MCMC simulation. This approach
ensured that a priori knowledge in the form of prior distributions
was ascribed only to those parameters that were identiﬁed as
having the greatest impact on variability. This is an eﬃcient
approach which helps reduce computational cost, i.e., simulation
times were signiﬁcantly reduced as reported previously (McNally
et al., 2012).
The SA also indicated that adipose mass (VFAC) did not
account for greater than 15.4% and respiratory rate (QPMC)
19.2%, of variance for CVxyl, CXppm, or Curine at any time.
Therefore, calculated values, adjusted to body weight, for both
parameters would have been adequate. An initial theoretical
modeling exercise during the design phase of the human study
may have provided enough conﬁdence to avoid measuring those
parameters for each volunteer. This could have represented
savings in time and cost.
The most dominant parameter governing variance during the
uptake and distribution phase of both CVxyl and CXppm, in the
presence or absence of inhibition of m-xylene metabolism by
ethanol was PBAXYL. PBAXYL is an indication of the solubility
of m-xylene in human blood which is consistent with a parameter
that is important in determining availability of m-xylene at the
site of metabolism in the liver. With the exception of CXppm
in the absence of inhibition, MPY was the most dominant
parameter during the elimination phase of CVxyl and CXppm,
which is also consistent with a parameter that determines the
rate of metabolism. In the presence of ethanol the proportion
of variance governed by PBAXYL and MPY increased for both
parameters during the latter elimination phase. This again is
consistent with parameters that are important in determining
elimination of m-xylene by exhalation when metabolism is
inhibited.
Calibration of PBAXYL and MPY using Bayesian inference
predicted values that were biologically plausible. For all three
outputs, CVxyl, CXppm, and Curine the MPY values were within
the 95% conﬁdence limit of the mean (Barter et al., 2007) as were
the PBAXYL values (McNally et al., 2012). It should be noted that
the variability in calibrated values for MPY are not necessarily
suggesting that microsomal protein yield changes dramatically
in the same individual from one study to the next – even when
separated by a month. It is a measure of the magnitude of the
contribution to variance by that parameter.
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FIGURE 7 | The full triangle symbols represent measured values for
volunteer A without prior ethanol administration, and the solid line is the
prediction. The full red circle symbols represent measured values with prior
ethanol administration, and the red broken line is the prediction. (A) shows
simulations without calibrated, and (B) with calibrated most sensitive
parameters (MPY and PBAXYL). Parameter abbreviations are listed in Table 4.
The binary chemical PBPK model, with a mechanism of
competitive inhibition of hepaticm-xylene metabolism, provided
satisfactory predictions for CVxyl and Curine although the
simulations of CXppm were over-predicted. It is plausible that the
measured exhaled concentrations of m-xylene were lower than
expected due to the diﬃculty in sampling the last 150 mL of
exhaled air assumed to be in equilibrium with pulmonary arterial
blood. In addition, the deviations betweenmodel predictions and
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FIGURE 8 | The full triangle symbols represent measured values for
volunteer E, without prior ethanol administration, and the solid line is
the prediction. The full circle symbols represent measured values, with prior
ethanol administration, and the broken line is the prediction. (A) Shows
simulations without calibrated, and (B) with calibrated most sensitive
parameters (MPY and PBAXYL). Parameter abbreviations are listed in Table 4.
data for end-exhaledm-xylene may be similar to the two possible
explanations proposed by Jonsson et al. (2001). The ﬁrst is that
the assumption of instant equilibrium between alveolar air and
arterial blood is not valid and the second that model parameters
are constant over time at a given workload.
The delay in reaching equilibrium between alveolar air
and arterial blood concentrations of several volatiles has been
observed in experimentally determined inhalation uptake studies
in rats (Johanson and Filser, 1992) and humans (Jonsson
and Johanson, 2001a). Further, exhaled concentrations of
mercury vapor were best predicted as originating from an
additional “respiratory depot” compartment in the respiratory
tract (Jonsson et al., 1999). Therefore, the lower measured,
end-exhaled concentrations of m-xylene may have originated
primarily from an upper respiratory tract depot with a much
smaller contribution from arterial blood.
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FIGURE 9 | The full triangle symbols represent measured values for
volunteer H, without prior ethanol administration, and the solid line is
the prediction. The full circle symbols represent measured values, with prior
ethanol administration, and the broken line is the prediction. (A) Shows
simulations without calibrated, and (B) with the calibrated most sensitive
parameter (MPY). Parameter abbreviations are listed in Table 4.
Variability in measured end-exhaled concentrations of
m-xylene (data not shown) may also be partly explained by the
variability in blood:air PCs form-xylene. Blood:air PCs for several
volatiles have been shown to increase after a meal (perhaps due
to variations in the blood lipids; Fiserova-Bergerova et al., 1980)
and may explain intra-individual variability in elimination by
exhalation and the latter process is inversely proportional to the
blood:air PC (Jonsson et al., 2001).
The binary model provided reasonable predictions for the
urinary excretion of 3-MHA. The expected delay in the
appearance of 3-MHA during inhibition ofm-xylene metabolism
was predicted. The marked switch from insigniﬁcant to
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signiﬁcant contribution to variance in urinary excretion of
3-MHA by MPY is noteworthy. This is consistent with the
importance of metabolism, without which 3-MHA could not be
produced. Rurine was the next most important parameter after
MPY, which is consistent with a process that governs the rate of
appearance of a metabolite in the urine.
In summary, a binary chemical PBPK model for ethanol
and m-xylene co-exposure, with an assumption of competitive
inhibition ofm-xylene metabolism, was used to analyze BM data
from a controlled human exposure study. Global SA provided
quantitative descriptions of the contributions to variance in the
model outputs, CVxyl, CXppm, and Curine. The identiﬁcation
of the most important parameters governing variance can be
used to reduce the computational cost of stochastic simulations.
Further, the use of this approach to PBPK model development
and analysis may be used to design eﬃcient and cost eﬀective
experimental studies.
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